Who are Placebo to dupilumab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dupilumab (SAR231893), Dupilumab therapy, Stopping dupilumab, Dupilumab Injectable Product, Dupilumab Prefilled Syringe, Dupilumab - Dose Reduction.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-to-dupilumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Placebo to dupilumab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo to dupilumab (Placebo to dupilumab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-4/IL-13 inhibitor. Area: Immunology.

phase 3 IL-4/IL-13 inhibitor IL-4Rα Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Placebo to dupilumab (Placebo to dupilumab) — AbbVie. Dupilumab is a monoclonal antibody that blocks the action of interleukin-4 (IL-4) and interleukin-13 (IL-13), which are key cytokines involved in the inflammatory process.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Placebo to dupilumab TARGET	Placebo to dupilumab	AbbVie	phase 3	IL-4/IL-13 inhibitor	IL-4Rα
Dupilumab (SAR231893)	Dupilumab (SAR231893)	Sanofi	marketed	IL-4 receptor antagonist monoclonal antibody	IL-4 receptor alpha (IL-4Rα)
Dupilumab therapy	Dupilumab therapy	National Medical Research Center for Children's Health, Russian Federation	marketed	Monoclonal Antibody	IL-4Rα
Stopping dupilumab	Stopping dupilumab	University Hospital, Toulouse	marketed	Monoclonal antibody	Interleukin-4 receptor alpha subunit (IL-4Rα)
Dupilumab Injectable Product	Dupilumab Injectable Product	University of Virginia	marketed	IL-4 receptor antagonist monoclonal antibody	IL-4 receptor alpha (IL-4Rα)
Dupilumab Prefilled Syringe	Dupilumab Prefilled Syringe	Jonathan A. Bernstein, MD	marketed	Monoclonal antibody; IL-4 receptor antagonist	IL-4 receptor alpha (IL-4Rα)
Dupilumab - Dose Reduction	Dupilumab - Dose Reduction	Johns Hopkins University	marketed	IL-4 receptor antagonist monoclonal antibody	IL-4 receptor alpha (IL-4Rα)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-4/IL-13 inhibitor class)

AbbVie · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo to dupilumab — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-to-dupilumab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab